Efficacy And Safety Of Tofacitinib In Chinese Subjects With Active Psoriatic Arthritis

PHASE3CompletedINTERVENTIONAL
Enrollment

204

Participants

Timeline

Start Date

August 10, 2018

Primary Completion Date

April 28, 2021

Study Completion Date

April 28, 2021

Conditions
Psoriatic Arthritis
Interventions
DRUG

Tofacitinib

tablets, 5 mg BID x 6 months

OTHER

Placebo

tablets, to match tofacitinib 5 mg BID x 3 months

DRUG

Tofacitinib

tablets, 5 mg BID x 3 months

Trial Locations (38)

100034

Peking University First Hospital, Beijing

100053

Rheumatology and Immunology Department, Xuanwu Hospital Capital Medical University, Beijing

100730

Peking Union Medical College Hospital, Beijing

150001

Rheumatology Department, The first Affiliated Hospital of Harbin Medical University, Harbin

200032

Zhongshan Hospital Fudan University, Shanghai

200040

Huashan Hospital, Fudan University, Shanghai

200052

Shanghai Guanghua Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai

210008

Nanjing Drum Tower Hospital, Nanjing

210029

Jiangsu Province Hospital, Nanjing

213003

Department of Rheumatology, The First People's Hospital of Changzhou, Changzhou

215006

Department of Rheumatology ,The First Affiliated Hospital of Soochow University, Suzhou

225001

Department of Rheumatology, Northern Jiangsu People's Hospital, Yangzhou

226001

Affiliated Hospital of Nantong University, Nantong

230001

Anhui Provincial Hospital, Hefei

230022

The First Affiliated Hospital of Anhui Medical University/Rheumatology Department, Hefei

233004

The First Affiliated Hospital of Bengbu Medical College, Bengbu

276003

Linyi People's Hospital, Linyi

300052

Tianjin Medical University General Hospital, Rheumatology and Immunology Department, Tianjin

310016

Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou

325000

The First Affiliated Hospital of Wenzhou Medical University, Wenzhou

332000

Jiu Jiang No.1 People's Hospital, Jiujiang

337055

Pingxiang People's Hospital, Pingxiang

361003

The First Affiliated Hospital of Xiamen University, Xiamen

400038

The First Affiliated Hospital of Army Medical University, PLA, Chongqing

410008

Xiangya Hospital Central South University, Changsha

410011

The Second Xiangya Hospital of Central South University, Changsha

412007

Zhuzhou Central Hospital, Zhuzhou

430022

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan

450052

The First Affiliated Hospital of Zhengzhou University, Zhengzhou

510080

The First Affiliated Hospital, Sun Yat-sen University, Guangzhou

510180

Guangzhou First People's Hospital, Guangzhou

510317

Guangdong Second Provincial General Hospital, Guangzhou

610041

Department of Rheumatology and Immunology,West China Hospital,Sichuan University, Chengdu

650032

First Affiliated Hospital of Kunming Medical University, Kunming

710061

The First Affiliated Hospital of Xi'an Jiaotong University, Xi’an

050051

The Third Hospital of Hebei Medical University, Rheumatology and Immunology Department, Shijiazhuang

014010

The First Affiliated Hospital of Baotou Medical College, Baotou

Unknown

The First hospital of Jilin University, Changchun

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT03486457 - Efficacy And Safety Of Tofacitinib In Chinese Subjects With Active Psoriatic Arthritis | Biotech Hunter | Biotech Hunter